Last Updated: November 9, 2026

Padagis Us Company Profile

« Back to Dashboard

What is the competitive landscape for PADAGIS US

PADAGIS US has ninety-two approved drugs.

There is one US patent protecting PADAGIS US drugs.

Summary for Padagis Us

US Patents:	1
Tradenames:	68
Ingredients:	63
NDAs:	92
Patent Litigation for Padagis Us:	See patent lawsuits for Padagis Us
PTAB Cases with Padagis Us as petitioner:	See PTAB cases with Padagis Us as petitioner

Drugs and US Patents for Padagis Us

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE	chlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride	SOLUTION;ORAL	204627-001	Apr 29, 2014		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Padagis Us	HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE	hydrocodone bitartrate; pseudoephedrine hydrochloride	SOLUTION;ORAL	204658-001	Apr 29, 2014		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Padagis Us	POTASSIUM CHLORIDE	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	205993-001	Nov 5, 2015	AB2	RX	No	No		⤷ Start Trial				⤷ Start Trial
Padagis Us	BACITRACIN ZINC AND POLYMYXIN B SULFATE	bacitracin zinc; polymyxin b sulfate	OINTMENT;OPHTHALMIC	065022-001	Feb 27, 2002		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Padagis Us	TROSPIUM CHLORIDE	trospium chloride	TABLET;ORAL	091573-001	Nov 17, 2010	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Padagis Us	POTASSIUM CHLORIDE	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	205993-002	Nov 5, 2015	AB2	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Padagis Us

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004	6,899,890	⤷ Start Trial
Padagis Us	BUTOCONAZOLE NITRATE	butoconazole nitrate	CREAM;VAGINAL	019881-001	Feb 7, 1997	4,078,071	⤷ Start Trial
Padagis Us	BUTOCONAZOLE NITRATE	butoconazole nitrate	CREAM;VAGINAL	019881-001	Feb 7, 1997	5,993,856	⤷ Start Trial
Padagis Us	EVAMIST	estradiol	SPRAY;TRANSDERMAL	022014-001	Jul 27, 2007	6,818,226	⤷ Start Trial
Padagis Us	EVAMIST	estradiol	SPRAY;TRANSDERMAL	022014-001	Jul 27, 2007	6,978,945	⤷ Start Trial
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004	5,993,856	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for PADAGIS US drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Vaginal Cream	2%	➤ Subscribe	2015-02-05
➤ Subscribe	Enteric Coated Capsules	3 mg	➤ Subscribe	2008-02-01

International Patents for Padagis Us Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Malaysia	144021	⤷ Start Trial
European Patent Office	1667619	⤷ Start Trial
Argentina	047108	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2005027807	⤷ Start Trial
Canada	2540129	⤷ Start Trial
Canada	2635992	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Padagis Us Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2957286	6/2019	Austria	⤷ Start Trial	PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721
1267866	C300583	Netherlands	⤷ Start Trial	PRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
0617614	11/2001	Austria	⤷ Start Trial	PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
1441735	2008/010	Ireland	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
2957286	132019000000021	Italy	⤷ Start Trial	PRODUCT NAME: PATIROMER SORBITEX CALCIUM E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721
2515855	122018000007	Germany	⤷ Start Trial	PRODUCT NAME: KOMBINATION VON GLYCOPYRRONIUMBROMID, FORMOTEROL ODER EINEM SALZ DAVON UND BECLOMETASONDIPROPIONAT; REGISTRATION NO/DATE: EU/1/17/1208 20170717
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.